Wall Street analysts predict that AstraZeneca plc (NYSE:AZN) will announce $0.44 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for AstraZeneca’s earnings, with estimates ranging from $0.42 to $0.46. AstraZeneca posted earnings of $1.12 per share during the same quarter last year, which would suggest a negative year over year growth rate of 60.7%. The company is expected to announce its next earnings report before the market opens on Thursday, November 8th.
According to Zacks, analysts expect that AstraZeneca will report full year earnings of $1.68 per share for the current fiscal year, with EPS estimates ranging from $1.65 to $1.70. For the next financial year, analysts anticipate that the business will post earnings of $1.89 per share, with EPS estimates ranging from $1.85 to $1.93. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for AstraZeneca.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 26th. The company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.38. The company had revenue of $5.16 billion for the quarter, compared to analyst estimates of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $0.87 earnings per share.
AZN has been the topic of a number of research analyst reports. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. ValuEngine lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Friday, September 7th. Zacks Investment Research lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, June 29th. Finally, Guggenheim initiated coverage on AstraZeneca in a research note on Monday. They issued a “buy” rating on the stock. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. AstraZeneca has an average rating of “Buy” and an average target price of $39.78.
In related news, major shareholder Plc Astrazeneca purchased 246,666 shares of the company’s stock in a transaction that occurred on Friday, September 28th. The shares were purchased at an average price of $15.00 per share, with a total value of $3,699,990.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
A number of institutional investors and hedge funds have recently modified their holdings of AZN. Jennison Associates LLC purchased a new position in AstraZeneca in the 2nd quarter worth about $676,716,000. FMR LLC boosted its position in AstraZeneca by 35.2% during the 2nd quarter. FMR LLC now owns 20,243,181 shares of the company’s stock worth $710,738,000 after acquiring an additional 5,272,590 shares during the period. Northern Trust Corp boosted its position in AstraZeneca by 45.2% during the 2nd quarter. Northern Trust Corp now owns 3,467,814 shares of the company’s stock worth $121,755,000 after acquiring an additional 1,079,790 shares during the period. Sei Investments Co. boosted its position in AstraZeneca by 293.5% during the 2nd quarter. Sei Investments Co. now owns 1,317,972 shares of the company’s stock worth $46,274,000 after acquiring an additional 983,055 shares during the period. Finally, Bank of Montreal Can boosted its position in AstraZeneca by 106.6% during the 3rd quarter. Bank of Montreal Can now owns 1,881,954 shares of the company’s stock worth $74,469,000 after acquiring an additional 970,857 shares during the period. 15.97% of the stock is currently owned by hedge funds and other institutional investors.
NYSE:AZN traded down $0.49 during mid-day trading on Friday, reaching $37.15. 3,709,900 shares of the stock were exchanged, compared to its average volume of 3,962,704. The firm has a market cap of $100.23 billion, a P/E ratio of 8.68, a PEG ratio of 2.10 and a beta of 0.58. AstraZeneca has a 1-year low of $31.99 and a 1-year high of $40.16. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Cash Flow Analysis in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.